| Autor: |
Lodaya RN; Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA.; GSK, Rockville Centre for Vaccines Research, Rockville, MD 20850, USA., Kanitkar AP; GSK, Rockville Centre for Vaccines Research, Rockville, MD 20850, USA., Ashraf A; GSK, Rockville Centre for Vaccines Research, Rockville, MD 20850, USA., Bamba D; GSK, Rockville Centre for Vaccines Research, Rockville, MD 20850, USA., Amiji MM; Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA., O'Hagan DT; GSK, Rockville Centre for Vaccines Research, Rockville, MD 20850, USA. |
| Abstrakt: |
The development of new vaccine adjuvants represents a key approach to improvingi the immune responses to recombinant vaccine antigens. Emulsion adjuvants, such as AS03 and MF59, in combination with influenza vaccines, have allowed antigen dose sparing, greater breadth of responses and fewer immunizations. It has been demonstrated previously that emulsion adjuvants can be prepared using a simple, low-shear process of self-emulsification (SE). The role of alpha tocopherol as an immune potentiator in emulsion adjuvants is clear from the success of AS03 in pandemic responses, both to influenza and COVID-19. Although it was a significant formulation challenge to include alpha tocopherol in an emulsion prepared by a low-shear process, the resultant self-emulsifying adjuvant system (SE-AS) showed a comparable effect to the established AS03 when used with a quadrivalent influenza vaccine (QIV). In this paper, we first optimized the SE-AS with alpha tocopherol to create SE-AS44, which allowed the emulsion to be sterile-filtered. Then, we compared the in vitro cell activation cytokine profile of SE-AS44 with the self-emulsifying adjuvant 160 (SEA160), a squalene-only adjuvant. In addition, we evaluated SE-AS44 and SEA160 competitively, in combination with a recombinant cytomegalovirus (CMV) pentamer antigen mouse. |
